BioNTech Results Presentation Deck
Preemptive Strategy to Address SARS-CoV-2 Variants
Establishing development, manufacturing and regulatory pathway for variant-specific prototype approach
Study Start
Nb of
participants (trial
phase)
Boosting
post dose 2
Data expected
17
March 2021
1
BNT162b2: 3rd dose
Safety & immunogenicity trial
N=23 (ph 1)
N=~300 (ph 2/3)
6-12 months
Prototype Approach substantiated by broad clinical data
First data published
July 2021
●
BNT162b2: 3rd dose
Safety & efficacy trial
2
N=~10,000 (ph 3)
6 months
Q4 2021
March 2021
●
3
Beta:
3rd dose or naïve
Safety & immunogenicity trial
●
N=-300 (ph 3)
N=~300 (naïve)
5-7 months
Q3 2021
4
Multivalent Delta + Alpha
or Delta or Alpha:
3rd dose or naïve:
Safety & immunogenicity trial
Expected August 2021
N=~600
N=~300 (naïve)
>6 months
Q4 2021
BIONTECHView entire presentation